Piramal Enterprises’ arm invests Rs 101.77 crore in Yapan Bio

21 Dec 2021 Evaluate

Piramal Enterprises’ subsidiary company -- Piramal Pharma (PPL) has invested Rs 101.77 crore in Yapan Bio (Yapan) of Hyderabad, India, augmenting the capabilities of its Contract Development and Manufacturing Organization (CDMO) business, Piramal Pharma Solutions (PPS). PPL holds 27.78% equity stake in the Yapan as a result of this investment.

As PPS continues to strengthen its capabilities and position itself as a leading CDMO, this acquisition marks a significant addition to PPS’ global capabilities in the development and manufacturing of large molecules for human clinical trials. The investment in Yapan Bio allows PPS to broaden its service offerings in the fast-growing biologics CDMO space. Biologics capabilities can be synergistic with the company's anti-body drug conjugation capabilities; specifically, for customers who prefer the speed and simplicity benefits of an integrated program that involves development, manufacturing, conjugation, and fill finish. PPS currently offers integrated payload, conjugation, fill finish services, and the addition of anti-body capabilities enhances that offering.

Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.

Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 1048.45
Shriram Finance 855.60
Aditya Birla Capital 358.85
Chola Invest & Fin. 1730.55
Tata Capital 325.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×